Pharmala Biotech (MDMA) Q3 2024 earnings summary

Executive summary

• Achieved approximately 10x revenue growth for the nine months ended May 31, 2024, compared to the same period in 2023, driven by expansion in Canada, Australia, and other ex-US markets.

• Strategy focuses on establishing leadership in clinical trial supply and prescriber markets for LaNeo MDMA.

Significant events and developments

• Cortexa joint venture is now permanent and irrevocable following completion of all intellectual property transfer requirements.

• US Patent Office issued patent 12042478 for APA-001, a novel MDXX class molecule with potential applications in anxiety and depression.

• Over $160,000 in non-dilutive grants accepted in 2024 to support global patent filings.

Capital allocation and financing

• CEO awarded a new contract with $170,000 annual salary and up to 50% bonus, plus 2 million RSUs vesting quarterly over one year.